Intralesional interleukin-2 augmentation therapy in treatment-refractory melanoma
Dermatol Ther
.
2022 Nov;35(11):e15853.
doi: 10.1111/dth.15853.
Epub 2022 Oct 6.
Authors
Stephanie T Le
1
,
Antonio Ji-Xu
1
,
William Liakos
1
,
Atrin M Toussi
1
,
Michelle Y Cheng
1
,
Chelsea Ma
2
,
Elizabeth A Wang
2
,
Reason Wilken
3
,
Sucharita Boddu
4
,
Lauren Downing
1
,
Jason Kao
5
,
Julian R Davis
6
,
Arta M Monjazeb
7
,
Maxwell A Fung
1
,
Thomas H Konia
1
,
Emanual Maverakis
1
,
Amanda R Kirane
2
8
Affiliations
1
Department of Dermatology, UC Davis School of Medicine, Sacramento, California, USA.
2
Department of Dermatology, Stanford University School of Medicine, Palo Alto, California, USA.
3
Department of Dermatology, Northwell Health, New York, New York, USA.
4
Department of Dermatology, Cleveland Clinic, Cleveland, Ohio, USA.
5
Department of Hematology/Oncology, Stanford University School of Medicine, Palo Alto, California, USA.
6
Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California, USA.
7
Department of Radiation Oncology, UC Davis School of Medicine, Sacramento, California, USA.
8
Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA.
PMID:
36151592
DOI:
10.1111/dth.15853
No abstract available
Publication types
Letter
MeSH terms
Humans
Immunotherapy
Injections, Intralesional
Interleukin-2
Melanoma* / drug therapy
Skin Neoplasms* / drug therapy
Substances
Interleukin-2
Grants and funding
P30CA09337/CA/NCI NIH HHS/United States